Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W V Epstein

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
The New England Journal of Medicine|February 12, 1998
Treatment of rheumatoid arthritis with a tumor necrosis factor receptor-Fc fusion proteinW V Epstein
The Medical Clinics of North America|March 1, 1977
Laboratory tests in rheumatic diseasesW V Epstein
The American Journal of Medicine|May 1, 1973
Immunologic events preceding clinical exacerbation of systemic lupus erythematosusW V Epstein
The Journal of Rheumatology|June 1, 1975
Specificity of SLE serum antibody for single-stranded and double-stranded DNA configurationW V Epstein
Bulletin on the Rheumatic Diseases|January 1, 1981
Health services research in rheumatologyW V Epstein
The Journal of Rheumatology|October 1, 1989
Parenteral gold therapy for rheumatoid arthritis: a treatment whose time has goneW V Epstein
Arthritis and Rheumatism|November 1, 1996
Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experienceW V Epstein
Seminars in Arthritis and Rheumatism|June 1, 1994
Efficacy of standard slow-acting antirheumatic drugsW V Epstein
Arthritis and Rheumatism|May 1, 1990
Economics and arthritisW V Epstein
Arthritis and Rheumatism|August 14, 1999
Blindedness in clinical trials of therapies for rheumatoid arthritis: comment on the article by Bresnihan et alW V Epstein
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
The New England Journal of Medicine|February 12, 1998
Treatment of rheumatoid arthritis with a tumor necrosis factor receptor-Fc fusion proteinW V Epstein
The Medical Clinics of North America|March 1, 1977
Laboratory tests in rheumatic diseasesW V Epstein
The American Journal of Medicine|May 1, 1973
Immunologic events preceding clinical exacerbation of systemic lupus erythematosusW V Epstein
The Journal of Rheumatology|June 1, 1975
Specificity of SLE serum antibody for single-stranded and double-stranded DNA configurationW V Epstein
Bulletin on the Rheumatic Diseases|January 1, 1981
Health services research in rheumatologyW V Epstein
The Journal of Rheumatology|October 1, 1989
Parenteral gold therapy for rheumatoid arthritis: a treatment whose time has goneW V Epstein
Arthritis and Rheumatism|November 1, 1996
Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experienceW V Epstein
Seminars in Arthritis and Rheumatism|June 1, 1994
Efficacy of standard slow-acting antirheumatic drugsW V Epstein
Arthritis and Rheumatism|May 1, 1990
Economics and arthritisW V Epstein
Arthritis and Rheumatism|August 14, 1999
Blindedness in clinical trials of therapies for rheumatoid arthritis: comment on the article by Bresnihan et alW V Epstein
Pageof 6